Anu Muona, PhD

Anu Muona is a founder and CEO of Aranda Pharma. Anu has over 7 years of experience on running preclinical drug discovery programs on cell therapy and small molecules. She has served as a Project manager of prostate cancer program at Medeia Therapeutics Ltd and been responsible for leading preclinical studies, building academic and CRO networks, participating in the strategic planning, IPR generation and partnering efforts. She has also been a member of a team exploring the potential of bone marrow stem cell-based therapy for the treatment of Alzheimer’s disease at Medeia Therapeutics Ltd. Anu has a strong scientific background in molecular biology and genetics. She received her PhD in molecular biology in the Collagen research unit of University of Oulu, Finland. She has completed extensive postdoctoral training in stem cell research and its applications in neurodegenerative diseases at the University of Eastern Finland, Kuopio.


Milla Koistinaho, PhD, Adjunct professor in Neurobiology

Milla Koistinaho is a founder and Non-Executive Director of Aranda Pharma Ltd. Milla has over 15 years of experience in commercializing biomedical inventions and developing business models especially in the therapeutic areas of CNS diseases and oncology. She has been a member of founding team in three start-up companies in Finland. For 9 years Milla has served as a founding CEO at Medeia Therapeutics Ltd and been responsible for IPR generation, leading research programs and partnerships, executing financing rounds and leading business development actions. Milla has also been CSO and CEO in Cerebricon Ltd serving clients in pharmaceutical development. She is well networked internationally and she has also worked as a postdoctoral researcher in biopharmaceutical projects at Eli Lilly and Company in the USA. Milla holds Adjunct Professorship in neurobiology at University of Eastern Finland. She has a PhD degree from the same university. Milla gained her PhD thesis in collaboration with Stanford University and Scios Inc., California, USA. Currently Milla is the Director of Life Sciences at the Helsinki Innovation Services Ltd, Finland.

Mr. Heikki Eronen

Heikki Eronen is a Manager in Company Administration and Finance at Aranda Pharma Ltd. Previously Heikki served in the same task at Medeia Therapeutics Ltd. Heikki brings over 40 years’ of experience to Aranda having served different small to medium-sized companies at various administrative and managerial roles. Heikki is a strong talent especially in accounting and financial planning.

Jari Koistinaho, MD, PhD, Professor of Pharmacology and Professor of Stem Cell Research

Jari Koistinaho is a founder and scientific collaborator in Aranda’s CNS programs. Jari is an internationally recognized neuroscientist with over 200 peer-reviewed scientific publications in the field of neuroinflammation and neurodegeneration. He has been a member of founding team in three spin-off companies in Finland that initially were based on the scientific expertise of his research group and he has also held several Board positions in Finnish biotech companies. Jari has spent several years in the USA as a visiting Professor at IUPUI School of Medicine, Department of Neurology and Stanford University Medical School, Department of Neurosurgery. He has also served as a Director of Biocenter Kuopio and as the Dean of A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland. Jari earned his M.D. and PhD degrees at University of Tampere, Finland. He currently leads Molecular Brain Research group at A.I. Virtanen Institute, University of Eastern Finland and holds positions of Professor of Pharmacology and Professor of Stem Cell Research in the same University.


Gundars Goldsteins, PhD, Adjunct Professor in Neurochemistry

Gundars Goldsteins is a founder and scientific collaborator in Aranda’s CNS programs. Gundars is internationally recognized neuroscientist and author of 38 publications centering on the role of oxidative stress in neurodegeneration. He has been a founding member of three start-up companies in Finland. Gundars received his PhD in Biochemistry at A.N. Bach Institute of Biochemistry, Moscow, Russia. He holds Adjunct Professorship in Neurochemistry at University of Eastern Finland. He is currently senior scientist at the University of Eastern Finland studying the role of oxidative stress for mitochondria in neurodegenerative diseases.


Xiao-Kun Zhang, PhD, Dean, Professor

Xiao-Kun Zhang is a Senior Scientific Advisor of Aranda Pharma Ltd. Xiao-Kun is internationally recognized nuclear hormone receptor scientist with over 120 peer-reviewed scientific publications, 9 US and 7 Chinese patents. He is among the first group of recipients of the China 1000 talent program. His groundbreaking research has led to discovery of novel target pathways for anticancer therapeutics and subsequent development of Targretin, approved by the FDA for the treatment of Cutaneous T-Cell Lymphoma, and TX803 currently developed for colorectal cancer by Tarrex Biopharma Ltd. Xiao-Kun received his PhD degree in Biochemistry from the University of Vermont, USA. He is a co-founder and Chief Scientific Advisor of Tarrex Biopharma Ltd, China. He currently holds positions of the Dean of School of Pharmaceutical Sciences at the Xiamen University, China and Professor of the Sanford-Burnham Medical Research Institute, California USA.